Skye Bioscience Reports 22.3% Weight Loss at 52 Weeks with Nimacimab Combination Therapy

summarizeSummary

Skye Bioscience reported strong 52-week interim data for its nimacimab and semaglutide combination therapy, showing 22.3% weight loss and reduced weight regain, positioning it competitively in the obesity market.

check_boxKey Events

• Significant Weight Loss Achieved

  Nimacimab combined with semaglutide achieved a mean weight loss of 22.3% at 52 weeks, with no plateau observed, demonstrating competitive efficacy.

• Enhanced Durability in Weight Management

  The combination therapy reduced weight regain by over 50% during a 13-week off-therapy follow-up compared to semaglutide alone (17.8% vs. 37.3%), indicating improved long-term efficacy.

• Favorable Safety and Tolerability Profile

  The combination treatment maintained a strong safety and tolerability profile over 52 weeks, with no serious adverse events or adverse events of special interest reported.

• Advancing to Higher-Dose Phase 2b Study

  The company plans to advance nimacimab into a Phase 2b study to evaluate higher doses and optimize the regimen, with full topline data from the Phase 2a extension expected in Q3 2026.

auto_awesomeAnalysis

Skye Bioscience announced highly positive interim 52-week results from its Phase 2a extension study of nimacimab in combination with semaglutide for obesity. The combination achieved a mean weight loss of 22.3% at 52 weeks, with no plateau observed, positioning it competitively against other leading obesity treatments. Crucially, the data also showed a significant reduction in weight regain during off-therapy follow-up, demonstrating enhanced durability compared to semaglutide alone. The therapy maintained a strong safety and tolerability profile. While the company's cash runway extends into Q4 2026, excluding the costs for a planned Phase 2b study, these robust clinical results significantly de-risk future financing efforts and support the advancement of nimacimab into higher-dose studies.